Post by M. Hawbaker on Jun 14, 2021 20:14:37 GMT
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) issued a recommendation that people who have previously suffered from capillary leak syndrome should not be inoculated with AstraZeneca’s AZN COVID-19 vaccine, Vaxzevria. The committee also recommended adding capillary leak syndrome as a side effect on Vaxzevria’s product label to increase awareness of this risk.
Capillary leak syndrome is a rare disorder characterized by massive leakage of plasma from blood vessels, which swells up arms and legs and results in low blood pressure, thickening of the blood and low blood levels of albumin.
The PRAC reviewed six cases of capillary leak syndrome in people, mostly women, given Vaxzevria. Three of the six people had a history of the condition while one of the persons died.
Capillary leak syndrome is a rare disorder characterized by massive leakage of plasma from blood vessels, which swells up arms and legs and results in low blood pressure, thickening of the blood and low blood levels of albumin.
The PRAC reviewed six cases of capillary leak syndrome in people, mostly women, given Vaxzevria. Three of the six people had a history of the condition while one of the persons died.
